186 related articles for article (PubMed ID: 9723307)
1. Low incidence of acute cellular rejection in liver transplantation with Neoral.
Imventarza O; Lendoire J; Bianco G; Saúl J; Braslavsky G; Trigo P; Cueto G; Duek F; Aziz H
Transplant Proc; 1998 Aug; 30(5):1854. PubMed ID: 9723307
[No Abstract] [Full Text] [Related]
2. Experience with neoral cyclosporine through the oral route in liver transplantation.
Bilbao I; Lazaro JL; Pou L; Charco R; Hildalgo E; Murio E; Margarit C
Transplant Proc; 1998 Jun; 30(4):1432-4. PubMed ID: 9636580
[No Abstract] [Full Text] [Related]
3. Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression.
Reggiani P; Rossi G; Latham L; Caccamo L; Gatti S; Maggi U; Melada E; Paone G; Doglia M; Vannelli A; Fassati LR
Transplant Proc; 1998 Aug; 30(5):1855-6. PubMed ID: 9723308
[No Abstract] [Full Text] [Related]
4. Reduced acute rejection and side effects with neoral in liver transplantation.
Tisone G; Vennarecci G; Pisani F; Baiocchi L; Mercadante E; Orlando G; Anselmo A; Casciani CU
Transplant Proc; 1998 Jun; 30(4):1430-1. PubMed ID: 9636579
[No Abstract] [Full Text] [Related]
5. Increased dosage requirement and rejection after Neoral conversion in pediatric liver transplant patients.
Cao S; Cox KL; Berquist W; So S; Concepcion W; Monge H; Esquivel CO
Transplant Proc; 1998 Dec; 30(8):4322-4. PubMed ID: 9865373
[No Abstract] [Full Text] [Related]
6. Comparison between tacrolimus and neoral cyclosporine administered by oral route in liver transplantation.
Bilbao I; Pou L; Allende E; Lázaro JL; Charco R; Hidalgo E; Margarit C
Transplant Proc; 2001 May; 33(3):2124-6. PubMed ID: 11377472
[No Abstract] [Full Text] [Related]
7. Low incidence of rejection after synchronous pancreas-kidney transplantation with Neoral.
Cattral MS; Hemming AW; Greig PD; Rowsell C; Chari R; Wright E; Donat D; Cole E; Levy GA
Transplant Proc; 1998 Aug; 30(5):1946. PubMed ID: 9723346
[No Abstract] [Full Text] [Related]
8. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.
Fischer L; Sterneck M; Gahlemann CG; Malago M; Rogiers X; Broelsch CE
Transplant Proc; 2000 Nov; 32(7):2125-7. PubMed ID: 11120098
[No Abstract] [Full Text] [Related]
9. Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application?
Haller GW; Winkler M; Bechstein WO; Oldhafer KJ; Ringe B; Maibücher A; Färber L; Pichlmayr R; Neuhaus P
Transplant Proc; 1996 Aug; 28(4):2239-40. PubMed ID: 8769211
[No Abstract] [Full Text] [Related]
10. Neoral without intravenous cyclosporine in liver transplantation.
Hemming AW; Greig PD; Cattral MS; Chung SW; Lilly LB; Aljumah AA; Levy GA
Transplant Proc; 1997; 29(1-2):543. PubMed ID: 9123121
[No Abstract] [Full Text] [Related]
11. Neoral versus Sandimmun: clinical impact and modification of immunosuppressive therapy in cardiac transplantation.
Maccherini M; Bernazzali S; Diciolla F; Giunti G; Bizzarri F; Lisi GF; Davoli G; Biagioli B; Giomarelli PP; Simeone F; Caciorgna M; Marchetti L; Pula G; Sani G; Toscano M
Transplant Proc; 1998 Aug; 30(5):1904-5. PubMed ID: 9723327
[No Abstract] [Full Text] [Related]
12. Neoral reduces the incidence of acute rejection after renal transplantation.
Sandrini S; Setti G; Gaggia P; Chiappini R; Maffeis R; Tardanico R; Maiorca R
Transplant Proc; 1998 Aug; 30(5):1758-9. PubMed ID: 9723269
[No Abstract] [Full Text] [Related]
13. Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial.
Sterneck M; Fischer L; Gahlemann C; Gundlach M; Rogiers X; Broelsch C
Ann Transplant; 2000; 5(1):43-6. PubMed ID: 10850611
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
Shah MB; Martin JE; Schroeder TJ; First MR
Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
[No Abstract] [Full Text] [Related]
15. Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation.
Samuel D; Bismuth H; Boillot O; Ducerf C; Baulieux J; Gugenheim J; Baldini E; Launois B; Messner M; Wolf P; Ellero E; Domergue J; Pageaux J; Cherqui D; Duvoux C; Durand F; Belghiti J; Calmus Y; Massault PP; Neau-Cransac M; Saric J; LeTreut Y; Campan P
Transplant Proc; 1998 Jun; 30(4):1394-6. PubMed ID: 9636563
[No Abstract] [Full Text] [Related]
16. Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group.
Grant D; Rochon J; Levy G
Transplant Proc; 1996 Aug; 28(4):2232-3. PubMed ID: 8769208
[No Abstract] [Full Text] [Related]
17. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus).
Van Buren D; Payne J; Geevarghese S; MacDonell R; Chapman W; Wright JK; Helderman JH; Richie R; Pinson CW
Transplant Proc; 1998 Jun; 30(4):1401-2. PubMed ID: 9636566
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of anti-rejection therapy by serum bile acids after liver transplantation.
Klar E; Theilmann L; Hoffmann V; Hofmann W; Kraus T; Mehrabi A; Herfarth C
Transplant Proc; 1998 Nov; 30(7):3567-9. PubMed ID: 9838562
[No Abstract] [Full Text] [Related]
19. Neoral as the initial immunosuppressant in liver transplantation; conversion from Sandimmune to Neoral in stable patients.
Kizilisik AT; al-Sebayel M; Ramirez CB
Transplant Proc; 1998 Nov; 30(7):3537-8. PubMed ID: 9838549
[No Abstract] [Full Text] [Related]
20. FK506 for primary and rescue therapy following liver transplantation.
Platz KP; Mueller AR; Zytowski M; Lobeck H; Neuhaus P
Transplant Proc; 1998 Jun; 30(4):1409-10. PubMed ID: 9636570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
